Day One

Explore challenges in delivering drugs to the olfactory region and trigeminal pathways with high precision

• Review strategies to navigate the nasal cavity for consistent CNS targeting
• Case studies highlighting successful intranasal delivery
• Current models to test olfactory delivery where are the gaps and the innovations?

• Explore emerging formulation and device strategies that increase direct brain uptake of drugs and biologics
• Understand approaches to minimize systemic exposure while maximizing CNS delivery for better efficacy and safety
• Gain insights into experimental and translational methods that can accelerate the development of CNS-targeted therapies

• Highlight general formulation and delivery learnings from model peptide/biologic compounds and how they pair with Aptar devices and proof of concept in vivo data
• Discuss formulation and device strategies to enable delivery of mucosal vaccines
• Emphasize using formulation, device, and in vivo studies to address problem statements in intranasal drug delivery with the following

The ideal opportunity to get face-to-face with many global nasal formulation and delivery leaders for important in-depth conversations.

• Understand the critical difference between producing batches for early studies versus large-scale commercial production.
• Learn how to assess partner capabilities, capital readiness and long-term vision to ensure they can support commercialization, not just development
• Explore strategies to align device design, manufacturing investment and regulatory timelines when capital and resources are constrained

• Review successes and failures in bringing intranasal drugs from concept to commercialization
• Examine strategies for driving adoption, demonstrating clinical value, and overcoming market inertia
• Learn practical tactics for optimizing launch timing, pricing, and market positioning

• Historically, airway mucus has been thought of as a simple layer of hydrogel on top of the epithelial cells, the “gel on cell” or “Gel/Sol” model. Over the past 15 years, airway mucus has been recognized as a more complex, two-layer “gel on brush” model
• Mucus in the nose is a variable component system. Mucin expression varies by anatomical location, disease, inflammation, aging, and physical stimulus.
• Each layer and mucus type has its own unique properties with regard to viscosity, elasticity, size exclusion, osmotic modulus, and other properties. This can have important ramifications for drug delivery, and is important to consider during the development phase.

• Formulation design isn’t just a supporting function — it’s an engine that shapes the full rheological fingerprint that determines how a nasal spray behaves the moment it leaves the nozzle.
• These material attributes drive the atomization event: droplet size, plume geometry, spray pattern, and ultimately where the dose lands. When we control the physics, we control the deposition.
• By tuning formulation parameters, we can intentionally shift deposition profiles unlocking optimized delivery for both local and systemic therapies.

• Explore approaches to solubilize and stabilize small molecules, biologics, and nucleic acids within limited nasal volumes
• Understand how viscosity and excipient selection impact dissolution, absorption, and formulation performance
• Discuss formulation design strategies to maximise therapeutic levels while maintaining patient safety

• Examine strategies to modulate mucoadhesion and overcome rapid clearance by the nasal mucosa
• Explore delivery approaches to optimize deposition and retention in target regions of the nasal cavity
• Learn how formulation-device integration can improve residence time and therapeutic outcomes

Witness some of the latest and greatest research in the nasal drug development & delivery field by drug developers, academics, service providers, and researchers in this spotlight poster session!

• Explore the impact of various formulation attributes on CNS and inner ear targeting
• Understand challenges in low-dose delivery and strategies to prevent underdosing
• Case study examples from a unique nasal formulation and delivery relief to recent onset tinnitus

• Compare powder versus liquid intranasal delivery, highlighting how deeper nasal deposition, increased surface area, and richer vascular access can drive faster and higher systemic absorption
• Explore the critical challenges of particle size distribution, particle shape, and limited large-scale manufacturing capacity, and how proprietary formulation strategies can address them
• Advancing powder-based naloxone and epinephrine programs, including device considerations, scalability planning, and where innovation is still needed across delivery technologies and manufacturing infrastructure